Richard Elion
Adult Medicine · Washington, DCNPI 1013948967
Payments from drug & device makers
Across 351 payments — averaging $9698.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$2.2M
- Viiv Healthcare Company$1.2M
- Merck$13K
- Janssen Products, LP$3K
- Janssen Scientific Affairs, LLC$2K
- Theratechnologies Inc.$2K
- plus $2K from 4 others
Across 4 payments — averaging $242.61 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Viiv Healthcare Company$970
What the payments were for
- Consulting fees$232,18465%
- Speaking & faculty fees$87,66024%
- Grants$1,6520%
- Travel & lodging$30,2738%
- Food & beverage$8,0782%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 180 | $2,188,695 |
| Viiv Healthcare Company | 126 | $1,193,769 |
| Merck | 10 | $13,233 |
| Janssen Products, LP | 4 | $3,440 |
| Janssen Scientific Affairs, LLC | 1 | $1,652 |
| Theratechnologies Inc. | 4 | $1,565 |
| GSK | 7 | $1,203 |
| Johnson & Johnson | 13 | $329 |
| AbbVie | 5 | $116 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few adult medicine providers in District of Columbiato place this figure against a meaningful peer group, so we don't.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 31 | $128,573 |
| JulucaDolutegravir/Rilpivirine | 13 | $52,897 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy | $2,188,695 | $128,57331 claims |
| Viiv Healthcare CompanyJuluca | $1,193,769 | $52,89713 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few adult medicine providers in District of Columbiaon file to place this against a meaningful peer group, so we don't.
Other adult medicine in Washington
- Sonia OkoloWashington$1K
- Manuel GonzalesWashington$178
- Reginald WillsWashington$134
- Margaret EtukeniWashington$106
- Annie BaileyWashington$24
- Adam ViscontiWashington$22
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.